IBDEI0RF ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12864,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,12864,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,12865,0)
 ;;=L56.0^^53^582^139
 ;;^UTILITY(U,$J,358.3,12865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12865,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,12865,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,12865,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,12866,0)
 ;;=L56.1^^53^582^138
 ;;^UTILITY(U,$J,358.3,12866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12866,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,12866,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,12866,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,12867,0)
 ;;=L56.2^^53^582^236
 ;;^UTILITY(U,$J,358.3,12867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12867,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,12867,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,12867,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,12868,0)
 ;;=L56.3^^53^582^268
 ;;^UTILITY(U,$J,358.3,12868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12868,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,12868,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,12868,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,12869,0)
 ;;=L57.0^^53^582^12
 ;;^UTILITY(U,$J,358.3,12869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12869,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,12869,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,12869,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,12870,0)
 ;;=L60.0^^53^582^161
 ;;^UTILITY(U,$J,358.3,12870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12870,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,12870,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,12870,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,12871,0)
 ;;=L60.1^^53^582^234
 ;;^UTILITY(U,$J,358.3,12871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12871,1,3,0)
 ;;=3^Onycholysis
 ;;^UTILITY(U,$J,358.3,12871,1,4,0)
 ;;=4^L60.1
 ;;^UTILITY(U,$J,358.3,12871,2)
 ;;=^186837
 ;;^UTILITY(U,$J,358.3,12872,0)
 ;;=L60.2^^53^582^233
 ;;^UTILITY(U,$J,358.3,12872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12872,1,3,0)
 ;;=3^Onychogryphosis
 ;;^UTILITY(U,$J,358.3,12872,1,4,0)
 ;;=4^L60.2
 ;;^UTILITY(U,$J,358.3,12872,2)
 ;;=^5009235
 ;;^UTILITY(U,$J,358.3,12873,0)
 ;;=L60.3^^53^582^170
 ;;^UTILITY(U,$J,358.3,12873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12873,1,3,0)
 ;;=3^Nail Dystrophy
 ;;^UTILITY(U,$J,358.3,12873,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,12873,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,12874,0)
 ;;=L60.4^^53^582^88
 ;;^UTILITY(U,$J,358.3,12874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12874,1,3,0)
 ;;=3^Beau's Lines
 ;;^UTILITY(U,$J,358.3,12874,1,4,0)
 ;;=4^L60.4
 ;;^UTILITY(U,$J,358.3,12874,2)
 ;;=^5009237
 ;;^UTILITY(U,$J,358.3,12875,0)
 ;;=L60.5^^53^582^290
 ;;^UTILITY(U,$J,358.3,12875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12875,1,3,0)
 ;;=3^Yellow Nail Syndrome
 ;;^UTILITY(U,$J,358.3,12875,1,4,0)
 ;;=4^L60.5
 ;;^UTILITY(U,$J,358.3,12875,2)
 ;;=^5009238
 ;;^UTILITY(U,$J,358.3,12876,0)
 ;;=L60.8^^53^582^168
 ;;^UTILITY(U,$J,358.3,12876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12876,1,3,0)
 ;;=3^Nail Disorders NEC
 ;;^UTILITY(U,$J,358.3,12876,1,4,0)
 ;;=4^L60.8
 ;;^UTILITY(U,$J,358.3,12876,2)
 ;;=^5009239
 ;;^UTILITY(U,$J,358.3,12877,0)
 ;;=L62.^^53^582^169
 ;;^UTILITY(U,$J,358.3,12877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12877,1,3,0)
 ;;=3^Nail Disorders in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,12877,1,4,0)
 ;;=4^L62.
 ;;^UTILITY(U,$J,358.3,12877,2)
 ;;=^5009241
 ;;^UTILITY(U,$J,358.3,12878,0)
 ;;=L64.9^^53^582^33
 ;;^UTILITY(U,$J,358.3,12878,1,0)
 ;;=^358.31IA^4^2
